A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Starting soon · Phase 1

Conditions studied: Healthy Participants

In brief

The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent

Key facts

Study ID

NCT07723118

Run by

Mirati Therapeutics Inc.

People needed

10

Starts

2026-08-05

Expected to finish

2026-09-12

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese).
• Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator.
• Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2.
• Participants must have Total body weight ≥ 50 kg.

You may not qualify if…

• Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
• Other protocol defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0001 — Anaheim, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.